William Blair Investment Management LLC Sells 17,842 Shares of West Pharmaceutical Services, Inc. $WST

William Blair Investment Management LLC lessened its stake in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 4.3% in the 3rd quarter, Holdings Channel.com reports. The firm owned 399,467 shares of the medical instruments supplier’s stock after selling 17,842 shares during the period. William Blair Investment Management LLC’s holdings in West Pharmaceutical Services were worth $148,106,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in West Pharmaceutical Services during the second quarter worth $2,387,990,000. State Street Corp grew its holdings in West Pharmaceutical Services by 1.7% in the 2nd quarter. State Street Corp now owns 3,348,698 shares of the medical instruments supplier’s stock valued at $1,202,183,000 after buying an additional 54,920 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in West Pharmaceutical Services in the 2nd quarter valued at $733,733,000. Generation Investment Management LLP purchased a new stake in West Pharmaceutical Services in the 2nd quarter valued at $728,168,000. Finally, Findlay Park Partners LLP acquired a new stake in shares of West Pharmaceutical Services in the 2nd quarter worth $214,196,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Down 0.0%

WST stock opened at $416.34 on Monday. West Pharmaceutical Services, Inc. has a one year low of $223.83 and a one year high of $438.27. The firm has a market cap of $29.00 billion, a PE ratio of 46.73, a PEG ratio of 2.53 and a beta of 1.13. The firm’s 50 day moving average price is $380.32 and its 200-day moving average price is $320.84. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.10 and a current ratio of 2.82.

West Pharmaceutical Services (NYSE:WST – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The medical instruments supplier reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.20 by $0.46. The company had revenue of $874.50 million during the quarter, compared to analyst estimates of $827.12 million. West Pharmaceutical Services had a return on equity of 21.78% and a net margin of 18.81%. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.96 earnings per share. On average, equities research analysts anticipate that West Pharmaceutical Services, Inc. will post 9.45 EPS for the current year.

West Pharmaceutical Services Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 18th. Shareholders of record on Wednesday, November 11th will be given a $0.26 dividend. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.22. This represents a $1.04 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date is Tuesday, November 10th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 11.67%.

Wall Street Analyst Weigh In

Several research analysts have recently commented on WST shares. Evercore reiterated an “outperform” rating and set a $425.00 price target on shares of West Pharmaceutical Services in a report on Monday, July 27th. UBS Group boosted their price target on shares of West Pharmaceutical Services from $340.00 to $415.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Barclays upped their price objective on shares of West Pharmaceutical Services from $440.00 to $500.00 and gave the company an “overweight” rating in a report on Friday, October 30th. TD Cowen raised their price objective on shares of West Pharmaceutical Services from $420.00 to $500.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Finally, Wall Street Zen raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Sunday, November 1st. Thirteen analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $424.67.

Read Our Latest Stock Report on WST

Insider Activity at West Pharmaceutical Services

In other news, VP Annette Favorite sold 8,135 shares of the company’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $340.81, for a total value of $2,772,489.35. Following the transaction, the vice president owned 16,845 shares of the company’s stock, valued at $5,740,944.45. This represents a 32.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders sold 15,659 shares of company stock valued at $5,443,749. Corporate insiders own 0.60% of the company’s stock.

West Pharmaceutical Services Profile

(Free Report)

West Pharmaceutical Services designs and manufactures packaging components and delivery systems used by the pharmaceutical, biotechnology, and medical device industries. Its products help contain and administer injectable medicines and include elastomeric components, such as stoppers and seals, as well as syringe components and other packaging and delivery solutions. The company also provides contract manufacturing services for medical devices and pharmaceutical delivery systems. Its customers include companies developing and producing branded, generic, and biologic medicines.

See Also

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Free Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.